Colchicine in Cardiac Surgery: The COCS Randomized Clinical Trial.

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery, increasing morbidity and mortality.
• Systemic inflammation is a known trigger for POAF development.
• Colchicine's anti-inflammatory properties suggest potential for POAF prevention, but prior evidence is inconclusive.

Purpose of the Study:

• To evaluate the efficacy of low-dose, short-term colchicine for preventing POAF in patients undergoing open-heart surgery.
• To assess the impact of colchicine on inflammatory markers and clinical outcomes post-cardiac surgery.

Main Methods:

• A double-blind, randomized, placebo-controlled trial involving 240 patients (113 colchicine, 127 placebo) after open-heart surgery.
• Colchicine or placebo was administered preoperatively and for five days postoperatively.
• Primary endpoint was POAF incidence; secondary endpoints included mortality, respiratory failure, stroke, bleeding, and inflammatory markers.

Main Results:

• POAF occurred in 18.6% of the colchicine group versus 30.7% in the placebo group (OR 0.515, p=0.029), indicating significant prevention.
• No significant differences were observed in secondary clinical outcomes like mortality or stroke.
• Inflammatory markers (pericardial/pleural effusion, WBC, neutrophil counts) showed significant differences on postoperative days 3 and 5.
• Adverse events, specifically diarrhea (25.7% vs 11.8%) and abdominal pain (7% vs 1.6%), were more frequent in the colchicine group.

Conclusions:

• Short-term, low-dose colchicine administration is effective in preventing POAF after coronary artery bypass grafting and/or aortic valve replacement.
• While effective for POAF prevention, colchicine use is associated with increased gastrointestinal side effects.
• Further research may explore optimized dosing or patient selection to mitigate side effects while maximizing POAF prevention benefits.